Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) is a remedy for type 2 diabetes mellitus (T2DM). Ex-4 ameliorates cardiac dysfunction induced by myocardial infarction in preclinical and clinical settings. However, it remains unclear whether Ex-4 may modulate diabetic cardiomyopathy. We tested the impact of Ex-4 on two types of diabetic cardiomyopathy models, genetic (KK) and acquired T2DM induced by high-fat diet [diet-induced obesity (DIO)], to clarify whether Ex-4 may combat independently of etiology. Each type of mice was divided into Ex-4 (24 nmol·kg−1·day−1 for 40 days; KK-ex4 and DIO-ex4) and vehicle (KK-v and DIO-v) groups. Ex-4 ameliorated systemic and cardiac insulin resistance and dyslipidemia in both T2DM models. T2DM mice exhibited systolic (DIO-v) and diastolic (DIO-v and KK-v) left ventricular dysfunctions, which were restored by Ex-4 with reduction in left ventricular hypertrophy. DIO-v and KK-v exhibited increased myocardial fibrosis and steatosis (lipid accumulation), in which were observed cardiac mitochondrial remodeling and enhanced mitochondrial oxidative damage. Ex-4 treatment reversed these cardiac remodeling and oxidative stress. Cytokine array revealed that Ex-4-sensitive inflammatory cytokines were ICAM-1 and macrophage colony-stimulating factor. Ex-4 ameliorated myocardial oxidative stress via suppression of NADPH oxidase 4 with concomitant elevation of antioxidants (SOD-1 and glutathione peroxidase). In conclusion, GLP-1R agonism reverses cardiac remodeling and dysfunction observed in T2DM via normalizing imbalance of lipid metabolism and related inflammation/oxidative stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191 · cited 2×
“Two types of T2DM models were allocated; genetic T2DM 85 model (KKAy) (14, 35) and age- and gender-matched (male) acquired T2DM mice fed with 86 high-fat diet (HFD60, Oriental Oriental Yeast, Tokyo, Japan) (32).”
MethodBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“accumulating evidence demonstrated that GLP-1R agonism ameliorates systolic dysfunction in 60 preclinical (2, 22) and clinical heart failure after ischemic heart disease (3, 20).”
BackgroundAguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010 · cited 5×
“Left panels; cardiac IRS-1 phosphorylation level 524 of KK mice treated with vehicle (KK-v) and with Ex-4 (KK-ex4).”
BackgroundInfluentialMitochondrial reactive oxygen species drive proinflammatory cytokine production
Naik, E., & Dixit, V. M. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110367 · Cited by 783 · cited 2×
“Growing evidences demonstrate that ROS links to inflammation and, in 300 particular, mitochondria-derived ROS could provoke the up-regulation of inflammatory 301 cytokines (21), suggesting the underlying mechanisms of the GLP-1 axis-mediated amelioration 302 of cardiac function could be explained at least two pathway…”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“GLP-1, one of the incretine hormones, has been focused not only as an alternative therapeutic 281 target for diabetes but also its pleiotropic effects on cardiovascular disease, including heart failure 282 related to pacing-induced heart failure (22), myocardial infarction (23), and obesity (24).”
BackgroundRijzewijk, L. J., van der Meer, R. W., Smit, J. W. A., Diamant, M., Bax, J. J., Hammer, S., Romijn, J. A., de Roos, A., & Lamb, H. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.062 · Cited by 559 · cited 1×
“, cardiac fibrosis, myocardial hypertrophy, and 67 steatosis of myocardium (29), at least in part, due to lipotoxity to heart (36).”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 1×
“Regarding TNFα, one of the cytokines modulating insulin resistance (15), it 263 remained unchanged; we further confirmed this trend by measuring the plasma TNFα level of 264 each mouse using ELISA (data not shown).”
MethodBoudina, S., Bugger, H., Sena, S., O'Neill, B. T., Zaha, V. G., Ilkun, O., Wright, J. J., Mazumder, P. K., Palfreyman, E., Tidwell, T. J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.792101 · Cited by 301 · cited 4×
“stress in heart, leading to cardiac remodeling and dysfunction (6).”
BackgroundInfluentialExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Cited by
Molecular mechanisms of diabetic cardiomyopathy
Bugger, H., & Abel, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3171-6 · Cited by 903
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Varga, Z. V., Giricz, Z., Liaudet, L., Haskó, G., Ferdinandy, P., & Pacher, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.030 · Cited by 286
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262
Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes
Levelt, E., Mahmod, M., Piechnik, S. K., Ariga, R., Francis, J. M., Rodgers, C. T., Clarke, W. T., Sabharwal, N., Schneider, J. E., Karamitsos, T. D., et al. (2016) · Diabetes · doi:10.2337/db15-0627 · Cited by 254
Metadata
- Authors
- Monji, A., Mitsui, T., Bando, Y. K., Aoyama, M., Shigeta, T., & Murohara, T.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2013-08-01
- Volume
- 305
- Issue
- 3
- Pages
- H295-H304
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2161531654
- Cited by
- 104
- References
- 14
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. https://app.cochat.ai/papers/10.1152/ajpheart.00990.2012
- The paper
- Monji, A., Mitsui, T., Bando, Y. K., Aoyama, M., Shigeta, T., & Murohara, T. (2013). Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. American Journal of Physiology-Heart and Circulatory Physiology. https://doi.org/10.1152/ajpheart.00990.2012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.